133 results on '"Pistola, L."'
Search Results
2. Concomitant high gene copy number and protein overexpression of IGF1R and EGFR negatively affect disease-free survival of surgically resected non-small-cell-lung cancer patients
3. Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations
4. Carboplatin plus pemetrexed for platinum-pretreated, advanced non-small cell lung cancer: a retrospective study with pharmacogenetic evaluation
5. Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival
6. Evaluation of the Prognostic Role of Vascular Endothelial Growth Factor and Microvessel Density in Stages I and II Breast Cancer Patients
7. PHARMACODYNAMIC STUDY OF SERUM EGFR AND HER2 IN PATIENTS WITH NON-SMALL CELL LUNG CANCER TREATED WITH ZD1839
8. THE ROLE OF ANGIOGENIC FACTORS AS PREDICTORS OF RESPONSE TO CISPLATIN AND GEMCITABINE CHEMOTHERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
9. Vascular endothelial growth factor serum levels (VEGFsI) in non-small cell lung cancer (NSCLC) patients: Correlation with histology and stage.
10. VASCULAR ENDOTHELIAL GROWTH FACTOR SERUM LEVELS (VEGFSL) IN NON SMALL CELL LUNG CANCER (NCSLC) PATIENTS: CORRELATION WITH HISTOLOGY AND STAGE
11. P1.01-65 Immune Gene Expression, Bayesian Network and Genetic Mutation Analysis in Advanced NSCLC Patients Treated with Immunotherapy
12. Pathway Activation Mapping of Kras Wild Type and Mutated Adenocarcinomas of the Lung: New Implications For Patient Stratification For Map Kinase Pathway Inhibition
13. Prognostic implications of epidermal growth factor receptor, KRAS and BRAF gene mutations in resected non-small cell lung cancer patients
14. Increased plasma levels of plasma free DNA levels in connective tissue diseases; a possible marker of disease activity in primary Sjogren’s syndrome
15. Increased plasma levels of circulating free DNA in patients with connective tissue diseases; a potential marker of disease activity in Sjogren’s syndrome
16. PROGNOSTIC AND PREDICTIVE ROLE OF PIK3CA MUTATIONS IN NON SMALL CELL LUNG CANCER PATIENTS TREATED WITH EGFR TYROSINE KINASE INHIBITORS (TKIS)
17. KRAS gene mutation testing an inter-laboratory validated workflow for quality assured, clinical-grade results using capillary electrophoresis
18. EGFR, KRAS, PIK3CA mutations and response to tyrosine kinase inhibitors (TKIs) in advanced NSCLC patients
19. Quantificazione del DNA circolante nelle malattie reumatiche autoimmuni: ipotesi su una possibile correlazione con l’attività di malattia
20. Analysis of human MDM4 variants in papillary thyroid carcinomas reveals new potential markers of cancer properties
21. Espressione dei recettori Her nei carcinomi non a piccole cellule del polmone
22. Effect of genetic polymorphisms (GP) on toxicity and survival in early breast cancer (EBC) patients (PTS) treated with adjuvant chemotherapy (CT)
23. Prognostic value of serum HER-2 in early stage breast cancer (BC) patients
24. ERCC1 and RRM1 mRNA expression in resected patients with non-small-cell-lung-cancer (NSCLC). (A study of the Perugia multidisciplinary team for thoracic tumors)
25. 'Determinazione dell’epidermal growth factor receptor nei carcinomi non a piccole cellule del polmone'. Congresso Italiano SIAPEC – IAP, Firenze 26-30 Settembre 2004
26. The role of genetic polymorphisms as predictive factors of toxitity and response to adjuvant treatment of early breast cancer
27. Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer
28. Predictors of resistance to chemotherapy and prognosis in advanced non-small cell lung cancer
29. Biological Prognostic Factors for early stage completely resected NSCLC
30. SIGNIFICATO PROGNOSTICO DI ALCUNI PARAMETRI BIOPATOLOGICI IN 99 CASI DI CARCINOMA DEL POLMONE NON-MICROCITOMA STADIO I-II. Atti congresso congiunto: Società italiana Anatomia Patologica e Citologia Diagnostica (SIAPEC) e International Academy of Pathology (IAP). Pathologica Vol 91
31. Analysis of human MDM4 variants in papillary thyroid carcinomas reveals new potential markers of cancer properties
32. Increased levels of circulating DNA in patients with systemic autoimmune diseases: A possible marker of disease activity in Sjögren’s syndrome
33. MYC and human telomerase gene (TERC) gene copy number gain in resected in non-small cell lung cancer (NSCLC).
34. Insulin-like growth factor receptor-1 (IGF1R) and epidermal growth factor receptor (EGFR) amplification and expression in surgically resected NSCLC.
35. Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of MET, EGFR, KRAS, and PIK3CA mutations.
36. Mutational analysis of KRAS, BRAF, and p53 genes in borderline and malignant epithelial ovarian tumors.
37. 9162 EGFR, KRAS, PIK3CA mutations and response to tyrosine kinase inhibitors (TKIs) in advanced NSCLC patients
38. 9050 NSCLC in never smokers, a different disease – a single institution retrospective evaluation
39. 9046 A phase II retrospective trial of Platinum/Gemcitabine (P/G)-based in first line treatment of advanced NSCLC with genetic polymorphisms analysis
40. 9081 A phase II retrospective trial of Carboplatin (CBDCA) and Alimta in refractory non-small cell lung cancer (NSCLC) with genetic polymorphisms analysis
41. Correlation of polymorphisms of genes involved in platinum/gemcitabine (P/G)-based metabolism with toxicity and clinical response in patients (pts) with advanced non-small cell lung cancer (NSCLC)
42. Effect of genetic polymorphisms on toxicity and survival in advanced non-small cell lung cancer (NSCLC) patients (pts) treated with carboplatin (CBDCA) and pemetrexed disodium regimen
43. 128PD EGFR, KRAS, PIK3CA MUTATIONS AND RESPONSE TO TYROSINE KINASE INHIBITORS (TKIS) IN ADVANCED NSCLC PATIENTS
44. EGFR, KRAS, PIK3CA mutations and response to tyrosine kinase inhibitors (TKIs) in advanced NSCLC patients
45. HER2, EGFR, PIK3CA mutations in HER2+ metastatic breast cancer (MBC) patients (pts) treated with trastuzumab (T): Incidence and correlation with response
46. 6522 POSTER EGFR mutations and response to TKIs therapy in NSCLC patients pre-treated with chemotherapy
47. Evaluation of HER-2 in serum and tissue: correlation with clinical-pathological parameters and outcome in early stage breast cancer (BC) patients (pts)
48. PD-157 Serum EGFR in patients with non-small cell lung cancer(NSCLC) treated with gefitinib
49. O-112 Microsatellite alterations and P53 mutations in tumor and plasma DNA of resected non small cell lung cancer (NSCLC) patients. (A study of the Perugia Multidisciplinary team for thoracic tumors)
50. 787 Pharmacodynamic study of serum EGFR and HER2 in patients with non-small cell lung cancer treated with ZD 1839
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.